According to a new study analyzing 2017 findings reported in JAMA Cardiology, fewer than one in three adults who were prescribed PCSK9 inhibitors–a new class of medications to treat patients with genetic conditions associated with high cholesterol–actually receive them. The new study from the Perelman School of Medicine at the University of Pennsylvania found that both public and private health insurers had significantly more prior authorization requirements for PCSK9 inhibitors than for two “comparator” medications. Some patients were even required to undergo genetic testing, which is typically not covered by insurance, to confirm the diagnosis of their condition before they could fill their prescriptions for the new class of cholesterol medications. Read more here.
Last Updated on May 13, 2020 by Aimed Alliance
